Source disclosure: March 06, 2026, 11:00 JST
Published by Pulse News Wire: March 06, 2026, 11:03 JST
Cuorips Inc. [4894.T]
TOKYO, Mar 06 (Pulse News Wire) – Cuorips Inc. (4894.T) secured conditional approval from the Ministry of Health, Labour and Welfare for its human induced pluripotent stem cell-derived cardiac sheet product, ReHeart, aimed at treating severe heart failure due to insufficient conventional treatments.
The approval allows for marketing under specific conditions and timelines, addressing unmet medical needs for patients who do not respond adequately to existing therapies such as medication and surgery. ReHeart is derived from healthy donor iPSCs and processed into sheets containing cardiac cells. It is designed to promote vascular regeneration around infarct areas through paracrine effects, potentially improving heart function and exercise tolerance. Previously, such patients had limited options like heart transplants or mechanical circulatory support, which come with significant risks and quality-of-life challenges.
With this approval, Cuorips aims to address these issues with a pioneering regenerative medicine solution. Looking ahead, Cuorips plans to swiftly apply for insurance coverage and initiate post-marketing surveillance involving 75 cases. Domestic sales are scheduled to commence in autumn 2026, with efforts also accelerating towards international markets. While there will be no impact on the current fiscal year's performance, the approval is expected to enhance long-term corporate value.
AI-translated content. 🟢 Confidence: High See terms • Original filing